BAKU, Azerbaijan, August 28. Investment in
Kazakhstan's pharmaceutical industry increased by 56% in 2025,
reaching $142.8 million, the press service of the Government of
Kazakhstan said.
This was announced in a statement by the press service of the
Kazakh Government.
According to the information, a further $7.1 million was
attracted in the first quarter of 2026. Major international
pharmaceutical companies, including AstraZeneca, Pfizer and Roche,
are participating in projects aimed at localizing production and
transferring technologies to Kazakhstan.
"Under the instruction of the Head of State, eight major
projects are being implemented to establish and expand
pharmaceutical production facilities. Their launch will make it
possible to produce more than 494 types of medicines in Kazakhstan
for the first time," the statement said.
The projects will cover medicines for the treatment of cancer,
cardiovascular, autoimmune, orphan and infectious diseases, as well
as diabetes.
The government noted that the development of Kazakhstan's
pharmaceutical industry is proceeding in several areas, ranging
from expanding domestic production and localizing technologies to
improving access to medicines in the regions.
Overall, pharmaceutical production in Kazakhstan has increased
by 37% over the past three years, reaching 191 billion tenge (about
$416 million).
Kazakhstan is continuing to modernize its healthcare system,
with efforts focused on expanding domestic pharmaceutical
production, developing medical infrastructure in the regions,
addressing healthcare staffing shortages, and introducing digital
technologies.
The measures are being implemented as part of the instructions
given by Kazakh President Kassym-Jomart Tokayev in his Address to
the People of Kazakhstan, "Kazakhstan in the Era of Artificial
Intelligence: Current Challenges and Their Solutions Through
Digital Transformation."
The President has instructed the government to increase the
volume and range of domestically produced medicines and introduce
modern digital tools to monitor the quality and volume of
healthcare services.
